IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES

被引：0
|
作者：
Nishimura, Takashi
Iwasa, Satoru
Shoji, Hirokazu
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
机构：
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-17-5
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: Experience of 154 patients with prognostic factor analysis
    Jo, Jae-Cheol
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Sym, Sun Jin
    Lee, Sung Sook
    Chang, Heung Moon
    Kim, Tae Won
    Lee, Jung Shin
    Kang, Yoon-Koo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (12) : 936 - 941
  • [32] Third-line chemotherapy with irinotecan and capecitabine (XELIRI) in advanced gastrointestinal (GI) cancer patients
    Mucciarini, Claudia
    Giovanardi, Filippo
    Cavanna, Luigi
    Artioli, Fabrizio
    ANNALS OF ONCOLOGY, 2005, 16 : 53 - 53
  • [33] Efficacy and safety of nivolumab and irinotecan as third-line chemotherapy for advanced gastric cancer: A multi-institutional retrospective study
    Kumanishi, Ryosuke
    Mitani, Seiichiro
    Kadowaki, Shigenori
    Matsushima, Tomohiro
    Takahashi, Naoki
    Ogata, Takatsugu
    Yasui, Hisateru
    Ogata, Misato
    Satake, Hironaga
    Narita, Yukiya
    Masuishi, Toshiki
    Bando, Hideaki
    Hara, Hiroki
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.
    Zhang, Zhe
    Chen, Zhiyu
    Zhu, Xiaodong
    Zhang, Xiaowei
    Zhao, Xiaoying
    Zhang, Wen
    Qiu, Lixin
    Huang, Mingzhu
    Wang, Chenchen
    Guo, Weijian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer
    Toshifumi Yamaguchi
    Satoru Iwasa
    Hirokazu Shoji
    Yoshitaka Honma
    Atsuo Takashima
    Ken Kato
    Tetsuya Hamaguchi
    Kazuhide Higuchi
    Narikazu Boku
    Gastric Cancer, 2019, 22 : 778 - 784
  • [36] Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Kato, Ken
    Hamaguchi, Tetsuya
    Higuchi, Kazuhide
    Boku, Narikazu
    GASTRIC CANCER, 2019, 22 (04) : 778 - 784
  • [37] Treatment outcome and safety of docetaxel as the third-line chemotherapy in advanced gastric cancer after progression or after failure of FOLFOX and FOLFIRI-based sequential chemotherapy
    Hwang, I.
    Kang, J.
    Park, B.
    Park, S.
    Jang, M.
    Kim, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [38] The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer
    Makiyama, A.
    Arimizu, K.
    Hirano, G.
    Makiyama, C.
    Matsushita, Y.
    Shirakawa, T.
    Ohmura, H.
    Komoda, M.
    Uchino, K.
    Inadomi, K.
    Kusaba, H.
    Shinohara, Y.
    Kuwayama, M.
    Kajitani, T.
    Esaki, T.
    Baba, E.
    ANNALS OF ONCOLOGY, 2016, 27 : 51 - 51
  • [39] Factors of the third-line treatment induction in advanced gastric cancer based on eligibility for clinical trials
    Sakumura, Miho
    Ando, Takayuki
    Hirano, Katsuhisa
    Miwa, Takeshi
    Motoo, Iori
    Kajiura, Shinya
    Ueda, Yuko
    Ogawa, Kohei
    Tsukada, Kenichiro
    Ueda, Akira
    Nakada, Naokatsu
    Hosokawa, Ayumu
    Fujii, Tsutomu
    Yasuda, Ichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S534 - S534
  • [40] Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer
    Soga, Norihito
    Kise, Hideaki
    Arima, Kiminobu
    Sugimura, Yoshiki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 376 - 381
12345